All data are based on the daily closing price as of October 30, 2025
e
Eisai
4523.TSE
29.71 USD
-0.01
-0.03%
Overview
Last close
29.71 usd
Market cap
8.38B usd
52 week high
44.70 usd
52 week low
24.09 usd
Target price
32.7 usd
Valuation
P/E
27.4163
Forward P/E
32.6797
Price/Sales
1.5799
Price/Book Value
1.6317
Enterprise Value
8.49B usd
EV/Revenue
1.6528
EV/EBITDA
12.4867
Key financials
Revenue TTM
5.22B usd
Gross Profit TTM
4.11B usd
EBITDA TTM
658.03M usd
Earnings per Share
1.07 usd
Dividend
1.04 usd
Total assets
9.78B usd
Net debt
-322.44M usd
About
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. The company offers Dayvigo, an orexin receptor antagonist for the treatment of insomnia; LEQEMBI, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody for Alzheimer's disease; Lenvima, an orally available multiple receptor tyrosine kinase inhibitor for the treatment of thyroid cancer and hepatocellular carcinoma, thymic carcinoma, renal cell carcinoma, and endometrial carcinoma; Fycompa, an anti-epileptic agent for primary generalized tonic-clonic seizures; and Halaven, a microtubule dynamics inhibitor for breast cancer and liposarcoma. It operates in Japan, China, the Americas, Europe, the Middle East, Africa, and East Asia Global South. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.